Equities research analysts expect that Unum Therapeutics Inc (NASDAQ:UMRX) will report $2.29 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Unum Therapeutics’ earnings. The lowest sales estimate is $1.70 million and the highest is $2.87 million. The business is scheduled to issue its next earnings results on Monday, February 11th.

On average, analysts expect that Unum Therapeutics will report full-year sales of $8.53 million for the current fiscal year, with estimates ranging from $7.30 million to $9.60 million. For the next financial year, analysts anticipate that the firm will report sales of $14.24 million, with estimates ranging from $7.50 million to $17.62 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last issued its earnings results on Monday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.01. The business had revenue of $2.04 million during the quarter, compared to the consensus estimate of $2.29 million.

Several equities research analysts have recently commented on UMRX shares. Wedbush boosted their price objective on Unum Therapeutics from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, August 14th. Cowen restated a “hold” rating on shares of Unum Therapeutics in a report on Monday, September 17th. Morgan Stanley boosted their price objective on Unum Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, October 11th. Finally, Zacks Investment Research downgraded Unum Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 17th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $20.67.

UMRX stock traded up $1.02 during mid-day trading on Thursday, reaching $7.82. The company’s stock had a trading volume of 744,846 shares, compared to its average volume of 263,023. Unum Therapeutics has a 12 month low of $6.75 and a 12 month high of $17.66.

In other news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction that occurred on Thursday, October 25th. The stock was sold at an average price of $8.46, for a total transaction of $97,163.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC boosted its position in shares of Unum Therapeutics by 4.3% during the second quarter. Jennison Associates LLC now owns 935,307 shares of the company’s stock valued at $13,305,000 after buying an additional 38,552 shares during the last quarter. Cowen Inc. purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $8,341,000. BlackRock Inc. purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $6,403,000. Wasatch Advisors Inc. boosted its position in shares of Unum Therapeutics by 5.3% during the second quarter. Wasatch Advisors Inc. now owns 267,625 shares of the company’s stock valued at $3,840,000 after buying an additional 13,525 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $1,485,000. Hedge funds and other institutional investors own 51.50% of the company’s stock.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Further Reading: Diversification in Investing

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.